Provided by Tiger Trade Technology Pte. Ltd.

Alterity Therapeutics Limited

4.55
+0.06001.34%
Post-market: 4.550.00000.00%16:10 EDT
Volume:13.20K
Turnover:59.51K
Market Cap:82.47M
PE:-4.93
High:4.72
Open:4.40
Low:4.40
Close:4.49
52wk High:5.89
52wk Low:2.66
Shares:18.13M
Float Shares:14.48M
Volume Ratio:0.51
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9231
EPS(LYR):-0.9231
ROE:-54.98%
ROA:-31.75%
PB:2.70
PE(LYR):-4.93

Loading ...

Company Profile

Company Name:
Alterity Therapeutics Limited
Exchange:
NASDAQ
Establishment Date:
1997
Employees:
9
Office Location:
500 Collins Street,Level 15,Melbourne,Victoria,Australia
Zip Code:
3000
Fax:
- -
Introduction:
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Directors

Name
Position
Julian Babarczy
Chairman of the Board and Director
Ann Cunningham
Director
Lawrence Gozlan
Director
Peter A. Marks
Director

Shareholders

Name
Position
David Stamler
Chief Executive Officer and Managing Director
Abby Macnish Niven
Chief Financial Officer and Company Secretary